atxn7l3 Antibody

What is ATXN7L3 and why is it important in molecular biology research?

ATXN7L3 is a component of the transcription regulatory histone acetylation (HAT) complex SAGA, a multiprotein complex that activates transcription by remodeling chromatin and mediating histone acetylation and deubiquitination. Within the SAGA complex, ATXN7L3 participates in a subcomplex that specifically deubiquitinates both histones H2A and H2B . The SAGA complex is recruited to specific gene promoters by activators such as MYC, where it is required for transcription. ATXN7L3 is required for nuclear receptor-mediated transactivation and plays a critical role in recruiting USP22 and ENY2 into the SAGA complex . It regulates H2B monoubiquitination (H2Bub1) levels and affects the subcellular distribution of ENY2, USP22, and ATXN7L3B . Understanding ATXN7L3 function provides insights into fundamental epigenetic regulation mechanisms.

What applications are ATXN7L3 antibodies typically used for in research?

ATXN7L3 antibodies are versatile tools employed in multiple experimental techniques:

These applications have been successfully employed to interrogate ATXN7L3's roles in various cellular contexts and disease models.

How should ATXN7L3 antibodies be stored and handled to maintain optimal performance?

For optimal performance of ATXN7L3 antibodies, storage at -20°C is recommended. Most commercial ATXN7L3 antibodies remain stable for 12 months when properly stored . Avoid repeated freeze-thaw cycles, as this can degrade antibody quality and reduce binding efficiency. Many commercial preparations contain glycerol (typically 50%) as a cryoprotectant . When shipping is required, use ice packs and store immediately at the recommended temperature upon receipt . Working aliquots can be prepared to minimize freeze-thaw cycles. Before use, centrifuge the antibody vial briefly to collect solution at the bottom of the tube. For Western blot applications, blocking with 5% non-fat milk in TBST is typically effective to reduce background.

What are common controls that should be included when using ATXN7L3 antibodies?

When designing experiments with ATXN7L3 antibodies, including appropriate controls is essential for result validation:

• Positive controls: Use cell lines known to express ATXN7L3 (most mammalian cell lines express detectable levels)

• Negative controls: Include secondary antibody-only controls to assess background

• Knockdown/knockout validation: siRNA or CRISPR depletion of ATXN7L3 serves as specificity control

• Peptide competition: Pre-incubation with immunizing peptide should abolish specific signal

• Cross-reactivity assessment: Test antibody on both human and mouse samples if working with both species

• Loading controls: Include appropriate housekeeping proteins (GAPDH, β-actin) for normalization in Western blots

For immunoprecipitation experiments, IgG from the same species as the ATXN7L3 antibody should be used as a negative control to assess non-specific binding.

How does the interaction between ATXN7L3 and ENY2 impact experimental design?

The interaction between ATXN7L3 and ENY2 is critical for experimental design because ENY2 significantly impacts ATXN7L3 stability. Studies have shown that depletion of ENY2 leads to substantial reduction of ATXN7L3 protein levels . This effect occurs post-transcriptionally, as ENY2 depletion reduced levels of exogenous ATXN7L3 as well . The stability of ATXN7L3 is tightly regulated by ENY2 interaction, suggesting that no free ATXN7L3 exists in mammalian cells .

Therefore, researchers should:

• Consider co-expression of ENY2 when overexpressing ATXN7L3

• Monitor ENY2 levels when studying ATXN7L3 function

• Be aware that ENY2 knockdown will indirectly affect ATXN7L3 levels

• Include both proteins in reconstitution experiments

• Remember that cooverexpression of ATXN7L3 and ENY2 can suppress ATXN7-poly(Q) aggregation in disease models

How can ATXN7L3 antibodies be used to study its role in hepatocellular carcinoma?

ATXN7L3 has been identified as a positive regulator of SMAD7 transcription in hepatocellular carcinoma (HCC) . For comprehensive investigation of ATXN7L3's role in HCC, researchers can implement the following approaches:

• Expression analysis: Use ATXN7L3 antibodies to compare protein levels between HCC and normal tissues through Western blot and IHC. Research has shown ATXN7L3 is lower expressed in HCC samples compared to normal tissue, with expression correlating with clinical outcomes .

• Chromatin binding studies: Employ ChIP-qPCR with ATXN7L3 antibodies to assess binding to the SMAD7 gene promoter. Studies indicate ATXN7L3 directly binds to the SMAD7 gene, regulating H2B ubiquitination levels .

• Mechanism investigation: Combine ATXN7L3 immunoprecipitation with mass spectrometry to identify binding partners in HCC cells. This approach revealed that ATXN7L3 participates in suppression of tumor growth both in vitro and in vivo .

• Clinical correlation: Use tissue microarrays with ATXN7L3 antibody staining to correlate expression with patient prognosis. The expression of ATXN7L3 has been shown to negatively correlate with clinical outcomes in HCC patients .

• Functional studies: After ATXN7L3 knockdown/overexpression, use antibodies to confirm altered protein levels before performing colony formation, cell growth, and xenograft tumor experiments .

A notable application example comes from research showing that ATXN7L3 expression strongly correlates with SMAD7 expression in HCC (Pearson correlation coefficient = 0.76, p < 0.001), suggesting coordinated regulation .

What methodologies are appropriate for investigating ATXN7L3's function in the SAGA deubiquitination module?

To comprehensively study ATXN7L3's role in the SAGA deubiquitination module (DUBm), researchers can employ these methodological approaches:

• Complex purification: Perform double-affinity purification using HA and Flag epitopes on different DUBm subunits to isolate stable complexes. This approach has successfully demonstrated that ATXN7L3 forms a stable complex with other DUBm components .

• Activity assays: Utilize Ub-AMC assays to measure deubiquitinating enzyme activity in isolated complexes. Research has shown no differences in activities between complexes containing normal or mutant ATXN7 .

• Complex integrity analysis: Combine HA immunoprecipitation with gel filtration to demonstrate that fully assembled DUB complexes elute with an apparent molecular mass of ~200 kDa .

• Substrate specificity: Conduct DUB assays using core histones or mononucleosomes as substrates to assess functional activity. Studies confirmed that normal and poly(Q)-expanded ATXN7 stimulated DUB activity to the same degree in vitro .

• Mutational analysis: Create deletion mutants of ATXN7L3 to identify domains critical for interaction with other DUBm components, particularly USP22, ENY2, and ATXN7 .

• Global impact assessment: Monitor global H2Bub1 levels by western blotting after ATXN7L3 depletion. Research demonstrates that H2Bub levels increase in cells expressing mutant ATXN7 .

Interestingly, comparative studies using these approaches revealed that while poly(Q) expansion in ATXN7 equivalent to that found in SCA7 patients does not affect the enzymatic activity of the SAGA DUBm in vitro, it leads to sequestration of DUBm components in vivo, impairing function .

How can researchers identify and characterize the UBTF::ATXN7L3 fusion in B-cell acute lymphoblastic leukemia?

The UBTF::ATXN7L3 fusion represents a novel biomarker in B-cell acute lymphoblastic leukemia (B-ALL) that requires specific detection methods:

• Transcriptome sequencing: RNA-Seq should be performed to detect the UBTF::ATXN7L3 fusion transcript. Studies identified this fusion in a distinct subset of previously unclassified BCP-ALL cases (n = 12 out of 568 adult BCP-ALL patients) .

• Genomic characterization: Whole-genome sequencing and SNP-arrays can confirm the underlying 17q21.31 microdeletion resulting in the fusion. This approach revealed that the fusion is driven by focal deletions .

• Expression profiling: Gene expression analysis shows that UBTF::ATXN7L3 cases form a distinct cluster with unique transcriptional signatures. Machine learning classifiers trained on gene expression profiles can help identify these cases .

• Antibody-based detection: Researchers should develop and validate antibodies specific to the fusion protein junction for diagnostic purposes. Standard ATXN7L3 antibodies may not effectively distinguish the fusion protein .

• Clinical correlation: Analysis of patient data revealed that CDX2/UBTF::ATXN7L3 ALL patients (n = 17/723, 2.4% of adult Ph-negative B-ALL) have distinct characteristics:

These patients show poor response to treatment with higher risk of relapse, emphasizing the clinical significance of identifying this fusion .

How do poly(Q) expansions in ATXN7 affect ATXN7L3 detection and function in spinocerebellar ataxia models?

In spinocerebellar ataxia type 7 (SCA7) models, poly(Q) expansions in ATXN7 create specific challenges for ATXN7L3 research:

• Aggregate formation: Poly(Q) expanded ATXN7 (ATXN7-92Q) forms nuclear aggregates that sequester DUBm components including ATXN7L3. Double immunofluorescence staining revealed that endogenous ATXN7L3 was present in nuclear inclusions in ~35% of astrocytes containing ATXN7-92Q aggregates (n = 86 aggregates) .

• Functional consequences: While in vitro biochemical studies showed that ATXN7-92Q NT stimulated DUB activity to the same degree as ATXN7-24Q NT, in vivo sequestration leads to increased global H2Bub levels, indicating impaired DUB activity .

• Detection challenges: When using antibodies for ATXN7L3 detection in poly(Q) expansion models, researchers should be aware that a significant portion of the protein may be sequestered in insoluble aggregates, potentially leading to underestimation in soluble fractions .

• Rescue strategies: Notably, cooverexpression of ATXN7L3 and ENY2 greatly inhibited aggregation of ATXN7-92Q and decreased the number of cells with more than 2 aggregates per nucleus from ~40% to ~10% . This intervention also reduced colocalization of ATXN7L3 with nuclear inclusions from ~35% to ~5% .

• Functional rescue: Cooverexpression of ATXN7L3 and ENY2 also opposed the increase in global H2Bub levels seen in ATXN7-92Q-expressing cells, suggesting DUB activity can be rescued . Interestingly, neither USP22 nor ENY2 alone produced this effect .

Research protocols should include fractionation steps to separate soluble and insoluble protein pools when working with poly(Q) expansion models to ensure accurate detection of ATXN7L3.

What techniques can be used to study interactions between ATXN7L3 and multiple deubiquitinating enzymes?

ATXN7L3 interacts with multiple deubiquitinating enzymes beyond USP22, requiring specific approaches to characterize these relationships:

• Affinity purification-mass spectrometry: This approach identified USP27X and USP51 as ATXN7L3 interacting proteins not previously known to be part of SAGA . Researchers purified FLAG- and V5-tagged ATXN7L3 from 293T cells and identified interacting proteins through mass spectrometry.

• Co-immunoprecipitation validation: After generating specific antibodies to USP27X and USP51, researchers confirmed interactions with ATXN7L3 by:

  • Immunoprecipitating FLAG-HA-ATXN7L3 and immunoblotting for USP27X/USP51

  • Immunoprecipitating endogenous ATXN7L3 from nuclear extracts and immunoblotting for USP27X/USP51

• Comparative complex purification: Researchers purified SAGA complex using FLAG- and HA-tagged GCN5 and probed for various components. While known SAGA components (TRRAP, ATXN7, ATXN7L3, USP22) were present, USP27X and USP51 were absent despite being well-expressed in these cells .

• Knockout/knockdown studies: Analysis in USP22 knockout mES cells revealed a substantial increase (~5-fold) in USP27X association with ATXN7L3 compared to wild-type cells, suggesting competitive binding . MudPIT analysis confirmed a ~5.5-fold increase of USP27X association with ATXN7L3 .

• Quantitative binding analysis: For precise quantification of binding affinities between ATXN7L3 and different DUBs, researchers can employ surface plasmon resonance (SPR) or isothermal titration calorimetry (ITC) using purified components.

These findings suggest ATXN7L3 can form multiple distinct protein complexes with different deubiquitinating enzymes, with potential redundancy and compensation mechanisms that should be considered when designing experiments targeting specific DUBs.

What considerations are important when using ATXN7L3 antibodies for quantitative proteomics applications?

When incorporating ATXN7L3 antibodies into quantitative proteomics workflows, researchers should address several technical considerations:

• Antibody specificity validation: Before use in proteomics applications, validate specificity through:

  • Western blot detection of expected ~40 kDa band

  • Signal reduction after siRNA/CRISPR knockout

  • Detection in both human and mouse samples if cross-species analysis is planned

• Epitope accessibility: Consider that ATXN7L3 exists in complexes with other proteins (USP22, ENY2, ATXN7) that may mask antibody epitopes. Use multiple antibodies targeting different regions when possible.

• Extraction conditions: Nuclear extraction protocols must be optimized, as ATXN7L3 is primarily nuclear-localized . Standard protocols include:

  • Hypotonic lysis followed by high-salt extraction

  • Sonication to disrupt nuclear membranes

  • Benzonase treatment to release chromatin-bound proteins

• Complexes vs. monomers: Consider whether experimental conditions should preserve protein complexes or isolate ATXN7L3. The strong effects of ATXN7L3 and ENY2 loss on H2B deubiquitination suggest these adaptors may facilitate the function of multiple H2B DUBs .

• Quantification calibration: For absolute quantification, use recombinant ATXN7L3 protein at known concentrations to create standard curves.

• Post-translational modifications: Be aware that some antibodies may have differential recognition depending on post-translational modifications of ATXN7L3.

• Normalization strategy: When comparing ATXN7L3 levels across samples, consider that traditional housekeeping proteins may not be appropriate if treatments affect general transcription or chromatin states.

The comprehensive characterization of the ATXN7L3 interactome has revealed its participation in multiple distinct protein complexes, suggesting broader roles beyond the canonical SAGA complex .

What are common issues when using ATXN7L3 antibodies and how can they be resolved?

Researchers working with ATXN7L3 antibodies may encounter several technical challenges:

For nuclear proteins like ATXN7L3, extraction efficiency is particularly critical. In one study, immunoblotting of column fractions indicated that the fully assembled DUB complex eluted with an apparent molecular mass of ~200 kDa , so extraction conditions must be optimized to preserve or disrupt these complexes as needed for the specific experimental question.

How can researchers distinguish between wild-type ATXN7L3 and the UBTF::ATXN7L3 fusion protein?

Distinguishing between wild-type ATXN7L3 and the UBTF::ATXN7L3 fusion protein requires specialized approaches:

• Custom junction antibodies: Develop antibodies targeting the unique fusion junction between UBTF and ATXN7L3. These should be validated against both wild-type proteins and fusion-positive control samples.

• Size discrimination: The fusion protein has a different molecular weight than wild-type ATXN7L3. Western blot analysis with standard ATXN7L3 antibodies can detect this size difference if resolution is sufficient.

• RT-PCR detection: Design primers spanning the fusion junction for specific amplification of the fusion transcript. This approach successfully identified the fusion in all cases of the distinct patient subset (n = 12/12 vs. n = 0/556 in the remaining cohort, p < 1E−10) .

• Differential localization: If the fusion alters nuclear localization patterns, immunofluorescence with standard ATXN7L3 antibodies might reveal distinct distribution patterns.

• Functional differences: The fusion may alter interactions with other SAGA components. Immunoprecipitation followed by Western blotting for known ATXN7L3 interactors can help distinguish the fusion protein.

• Genomic verification: Confirm fusion presence through FISH or genomic PCR detecting the underlying 17q21.31 microdeletion that creates the fusion.

The comprehensive identification approach used in research combined RNA-Seq for fusion transcript detection with machine learning classifiers trained on gene expression profiles, followed by confirmation of corresponding genomic alterations using whole-genome sequencing, whole-exome sequencing, and SNP arrays .

What factors affect ATXN7L3 stability and how might this impact antibody-based detection?

ATXN7L3 stability is regulated by several factors that researchers should consider when using antibodies for detection:

• ENY2 interaction: ENY2 dramatically affects ATXN7L3 stability. Depletion of ENY2 led to significant reduction of ATXN7L3 protein levels, and ATXN7L3 levels were restored upon stable expression of exogenous ENY2 . This effect occurs post-transcriptionally, as ENY2 depletion also reduced levels of exogenous ATXN7L3 .

• Complex formation: ATXN7L3 stability increases when incorporated into protein complexes. In baculovirus expression systems, the solubility of ATXN7-92Q was improved upon coexpression of other DUBm subunits .

• Aggregation sequestration: In disease models (e.g., SCA7), ATXN7L3 can be sequestered in insoluble aggregates, potentially leading to underestimation in soluble fractions. Approximately 35% of aggregates containing ATXN7-92Q also contained ATXN7L3 .

• Extraction conditions: The buffers and protocols used for protein extraction significantly impact ATXN7L3 recovery. Standard nuclear extraction protocols may not efficiently solubilize all ATXN7L3, particularly when in large complexes or aggregates.

• Proteasomal degradation: Free ATXN7L3 not incorporated into complexes may be subject to proteasomal degradation, suggesting that proteasome inhibitors might increase detection levels.

To address these stability factors:

• Always include ENY2 status assessment when studying ATXN7L3

• Consider non-denaturing extraction conditions to preserve complexes if studying interactions

• Use fractionation approaches to assess both soluble and insoluble pools

• Include protease inhibitors in all extraction buffers

• Be aware that treatment effects on ATXN7L3 levels may be indirect, through effects on ENY2 or complex formation

What emerging applications of ATXN7L3 antibodies show promise for understanding disease mechanisms?

Several emerging applications of ATXN7L3 antibodies show potential for elucidating disease mechanisms:

• Single-cell proteomics: Applying ATXN7L3 antibodies in single-cell analyses could reveal cell-to-cell variation in expression and localization, particularly important in heterogeneous diseases like cancer.

• Proximity labeling: Combining ATXN7L3 antibodies with BioID or APEX2 proximity labeling can identify context-specific interactors in different disease states, potentially revealing novel therapeutic targets.

• Liquid biopsy development: Exploring ATXN7L3 or UBTF::ATXN7L3 fusion detection in circulating tumor cells or cell-free DNA could enable less invasive monitoring of diseases like B-ALL, where the fusion is associated with poor prognosis .

• Super-resolution microscopy: Using highly specific ATXN7L3 antibodies with techniques like STORM or PALM could reveal precise nuclear organization patterns of SAGA complexes in normal versus disease states.

• Therapeutic monitoring: In HCC, where ATXN7L3 expression negatively correlates with clinical outcomes , antibody-based monitoring could help assess treatment efficacy.

• Combinatorial epigenetic profiling: Multiplexed antibody approaches combining ATXN7L3 with other chromatin modifiers could map the epigenetic landscape changes during disease progression.

The discovery that ATXN7L3 positively regulates SMAD7 transcription and suppresses HCC progression suggests it may have potential as a therapeutic marker . Similarly, the poor prognosis associated with UBTF::ATXN7L3 fusion in B-ALL (75.0% vs 32.4% relapse rate, p=0.004) indicates its value as a stratification marker for intensive therapy approaches.

How can ATXN7L3 antibodies contribute to understanding the broader roles of the SAGA complex in gene regulation?

ATXN7L3 antibodies offer powerful tools for investigating the expanding roles of the SAGA complex in gene regulation:

• Genome-wide mapping: ChIP-seq using ATXN7L3 antibodies can map the genomic binding sites of the deubiquitination module, potentially revealing locus-specific recruitment mechanisms and comparing these to the distribution of other SAGA components.

• Temporal dynamics: Time-course studies with ATXN7L3 antibodies can elucidate the sequential assembly and function of SAGA subcomplexes during transcriptional activation and repression.

• Alternative complex identification: The discovery that ATXN7L3 interacts with USP27X and USP51 outside the canonical SAGA complex suggests ATXN7L3 antibodies could help identify and characterize novel transcriptional regulatory complexes.

• Context-specific function: Comparing ATXN7L3 binding and activity across different cell types and developmental stages could reveal tissue-specific roles of the SAGA complex.

• Disease-altered function: Investigating how pathological conditions affect ATXN7L3 localization and interactions may reveal dysregulated epigenetic mechanisms. For example, the significant increase (~5-fold) in USP27X association with ATXN7L3 in USP22 knockout cells suggests compensatory mechanisms that might be targeted therapeutically.

• Cross-talk with other pathways: Using ATXN7L3 antibodies in conjunction with antibodies against components of other epigenetic regulators could help map the intricate networks of chromatin modifiers that coordinate gene expression.

The strong positive correlation established between ATXN7L3 and SMAD7 mRNA levels in HCC samples demonstrates how ATXN7L3 antibodies can help uncover unexpected roles of this protein beyond its canonical function in the SAGA complex.

What are the optimal protocols for using ATXN7L3 antibodies in chromatin immunoprecipitation experiments?

For successful chromatin immunoprecipitation (ChIP) experiments using ATXN7L3 antibodies, researchers should consider these optimized protocols:

• Crosslinking optimization:

  • Use 1% formaldehyde for 10 minutes at room temperature

  • Consider dual crosslinking with DSG (disuccinimidyl glutarate) followed by formaldehyde for enhanced detection of protein-protein interactions within SAGA complex

  • Quench with 125 mM glycine for 5 minutes

• Chromatin fragmentation:

  • Sonicate to achieve fragments of 200-500 bp

  • Verify fragmentation by agarose gel electrophoresis

  • Over-sonication can destroy epitopes recognized by ATXN7L3 antibodies

• Immunoprecipitation conditions:

  • Pre-clear chromatin with protein A/G beads

  • Use 3-5 μg of ATXN7L3 antibody per ChIP reaction

  • Include IgG control from same species as ATXN7L3 antibody

  • Incubate overnight at 4°C with rotation

• Washing stringency:

  • Low salt wash buffer (150 mM NaCl)

  • High salt wash buffer (500 mM NaCl)

  • LiCl wash buffer (250 mM LiCl)

  • TE buffer wash

• DNA recovery and analysis:

  • Reverse crosslinks at 65°C for 4-6 hours

  • Treat with RNase A and Proteinase K

  • Purify DNA using phenol-chloroform extraction or commercial kits

  • Analyze by qPCR, focusing on known SAGA-regulated promoters

• Controls and validation:

  • Input DNA control (typically 1-10% of starting material)

  • Positive control loci (genes known to be regulated by SAGA)

  • Negative control regions (gene deserts)

  • Parallel ChIP with antibodies against other SAGA components for confirmation

For ChIP-seq applications, ensure library preparation maintains the representation of immunoprecipitated DNA fragments and use appropriate peak-calling algorithms that account for the typically broad binding patterns of chromatin modifiers like SAGA components.

How should researchers approach the development of antibodies specific to the UBTF::ATXN7L3 fusion protein?

Developing antibodies specific to the UBTF::ATXN7L3 fusion protein requires a systematic approach:

• Fusion junction analysis:

  • Determine the exact amino acid sequence at the fusion junction

  • Analyze the junction for immunogenicity and uniqueness

  • Ensure the junction region is not buried within the protein structure

• Peptide design strategies:

  • Design peptides spanning the fusion junction (typically 15-25 amino acids)

  • Include 7-10 amino acids from each fusion partner

  • Ensure the junction is centered in the peptide

  • Add a C-terminal cysteine for conjugation if not present naturally

• Immunization approaches:

  • Use multiple host animals (rabbits, mice, guinea pigs) for diversity of responses

  • Consider different adjuvants to enhance immunogenicity

  • Implement longer immunization schedules for challenging epitopes

• Screening methodology:

  • Screen antibodies against the immunizing peptide by ELISA

  • Test against both wild-type UBTF and ATXN7L3 to exclude cross-reactivity

  • Validate on cells expressing the fusion protein (e.g., B-ALL patient samples)

  • Verify specificity using Western blot, immunofluorescence, and immunoprecipitation

• Validation considerations:

  • Use CRISPR-engineered cell lines expressing the fusion protein as positive controls

  • Include non-fusion expressing cells as negative controls

  • Verify recognition of the fusion protein at expected molecular weight

  • Confirm lack of reactivity with individual wild-type proteins

• Application optimization:

  • Determine optimal dilutions for each application (Western, IF, IHC)

  • Establish fixation and antigen retrieval conditions for IHC

  • Optimize blocking solutions to minimize background

The development of such specific antibodies would greatly facilitate the identification and study of CDX2/UBTF::ATXN7L3 ALL, which represents approximately 2.4% of adult Ph-negative B-ALL cases and is associated with significantly poorer outcomes .

What resources are available for researchers seeking to use ATXN7L3 antibodies in their studies?

Researchers working with ATXN7L3 antibodies can leverage several resources:

• Commercial antibodies:

  • Monoclonal antibodies like clone 2ATX-2B1 (MA3-084) from Thermo Fisher have been validated for Western blot, immunofluorescence, and ELISA

  • Polyclonal antibodies such as E-AB-18358 from Elabscience have been validated for IHC applications

  • Bethyl Laboratories' anti-ATXN7L3 (Cat#A302-800A) has been cited in multiple peer-reviewed studies

• Antibody validation databases:

  • Antibodypedia provides user reviews and validation data

  • The Antibody Registry assigns unique identifiers to antibodies

  • Human Protein Atlas includes immunohistochemistry data for ATXN7L3

• Protocol repositories:

  • Bio-protocol for detailed, peer-reviewed experimental procedures

  • Protocols.io for community-shared methodologies

  • Nature Protocol Exchange for cutting-edge techniques

• Reagent sharing platforms:

  • Addgene for plasmids expressing tagged versions of ATXN7L3

  • NIGMS Human Genetic Cell Repository for disease-relevant cell lines

  • ENCODE project data for chromatin binding profiles

• Bioinformatics tools:

  • GEPIA for gene expression correlation analysis between ATXN7L3 and other genes

  • cBioPortal for exploring ATXN7L3 alterations across cancer types

  • UCSC Genome Browser for visualizing ATXN7L3 binding sites

• Disease models:

  • ATXN7-92Q expressing cell lines for studying SCA7-related mechanisms

  • UBTF::ATXN7L3 fusion-positive patient-derived xenograft models for B-ALL studies

Researchers should note that while multiple commercial antibodies are available, validation in the specific experimental context remains essential, particularly for complex applications like ChIP or when studying disease-specific alterations of ATXN7L3.

What are the most important recent findings related to ATXN7L3 that researchers should be aware of?

Several key recent discoveries about ATXN7L3 have significant implications for researchers:

• Tumor suppressor role in HCC: ATXN7L3 positively regulates SMAD7 transcription in hepatocellular carcinoma and functions in tumor growth suppression both in vitro and in vivo. ATXN7L3 is lower expressed in HCC samples compared to normal tissues, with its expression negatively correlating with clinical outcomes .

• Novel B-ALL subtype marker: The UBTF::ATXN7L3 fusion defines a novel high-risk subtype of B-cell acute lymphoblastic leukemia. This subtype represents approximately 2.4% of adult Ph-negative B-ALL cases, predominantly affects young female patients, and is associated with significantly poorer outcomes including higher relapse rates (75.0% vs 32.4%, p=0.004) .

• Multiple DUB interactions: ATXN7L3 associates with USP27X and USP51 in addition to the canonical USP22 interaction, suggesting broader roles in regulating histone deubiquitination. In USP22 knockout cells, ATXN7L3's association with USP27X increases ~5-fold, indicating compensatory mechanisms .

• Role in SCA7 pathology: Poly(Q) expansions in ATXN7 cause aggregation that sequesters ATXN7L3 and other DUBm components, impairing DUB activity. Interestingly, cooverexpression of ATXN7L3 and ENY2 suppresses ATXN7-92Q aggregation and rescues DUB activity in vivo, suggesting potential therapeutic approaches .

• ENY2-dependent stability: ATXN7L3 stability is critically dependent on ENY2, with depletion of ENY2 leading to substantial reduction of ATXN7L3 protein levels. This effect occurs post-transcriptionally and suggests that no free ATXN7L3 exists in mammalian cells .

• Global gene regulation: Beyond its known role in the SAGA complex, ATXN7L3 has been shown to globally regulate a series of genes, suggesting broader transcriptional regulatory functions .